Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation.
Reddiconto
Giovanni
G
Chiusolo
Patrizia
P
Fiorini
Alessia
A
Farina
Giuliana
G
Sorà
Federica
F
Leone
Giuseppe
G
Sica
Simona
S
D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D045744:Cell Line, Tumor; D046528:Chimerism; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000494:pharmacology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D012008:Recurrence; D012074:Remission Induction; D013844:Thiazoles / Q000494:pharmacology*; D013997:Time Factors
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib